STOCK TITAN

Candel Therapeutics, Inc. - CADL STOCK NEWS

Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.

Candel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company pioneering viral immunotherapies for solid tumor treatment. This page serves as the definitive source for official updates on the company's innovative adenovirus and herpes simplex virus (HSV) platform developments.

Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes press releases detailing therapy advancements, peer-reviewed research collaborations, and manufacturing updates relevant to CADL's immuno-oncology pipeline.

Key content categories include phase trial results, FDA communications, intellectual property developments, and executive leadership announcements. All materials are sourced directly from company filings and verified channels to ensure accuracy.

Bookmark this page for streamlined access to Candel Therapeutics' latest developments in cancer immunotherapy. Check regularly for updates on their gmci™ and rqnestin34.5 platforms as they progress through clinical evaluation.

Rhea-AI Summary
Candel Therapeutics announces positive results from the first-in-human clinical trial of CAN-3110 in recurrent high-grade glioma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
-
Rhea-AI Summary
Candel Therapeutics to present three posters at SITC Annual Meeting, including clinical trial data for CAN-2409 in pancreatic cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9%
Tags
none
-
Rhea-AI Summary
Candel Therapeutics announces updated activity data from its phase 2 clinical trial of CAN-2409 in non-small cell lung cancer patients. The data shows an encouraging number of long survivors, with 10 patients living over 18 months and 4 patients living over 24 months. These patients had low or negative PD-L1 expression, suggesting CAN-2409's potential to convert immunosuppressive tumors into long-term survivors. Biomarker data also indicates a correlation between immune cell activation and survival. Overall survival data for Cohort 2 is expected in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.71%
Tags
Rhea-AI Summary
Candel Therapeutics to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
conferences
-
Rhea-AI Summary
Candel Therapeutics, Inc. reported financial results for Q2 2023, with research and development expenses of $5.9 million and a net loss of $9.6 million. The company expects to announce additional clinical and immunological biomarker data in Q3 and Q4. Cash and cash equivalents as of June 30, 2023, were $51.9 million, sufficient to fund operations until Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. announced that its CEO will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference. The chat will be webcasted live and a replay will be available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
management
-
Rhea-AI Summary
Candel Therapeutics to present at Jefferies Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.8%
Tags
conferences
Rhea-AI Summary
Candel Therapeutics announces new data from a phase 1 clinical trial of its viral immunotherapy candidate, CAN-3110, in patients with recurrent high-grade glioma. The data shows encouraging overall survival rates and no dose-limiting toxicities. The company is enrolling patients for a repeat dosing regimen to further improve results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.13%
Tags
Candel Therapeutics, Inc.

Nasdaq:CADL

CADL Rankings

CADL Stock Data

215.87M
38.51M
18.54%
44.13%
7.5%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEEDHAM